Brief: Editas Medicine Says Positive Initial Edit-301 Safety And Efficacy Data From First Four Patients Treated In Ruby Trial And First Patient Treated In The Edithal Trial

Editas Medicine

09/06/2023 08:09

June 9 (Reuters) - Editas Medicine Inc  EDIT.O :
    * EDITAS MEDICINE ANNOUNCES POSITIVE INITIAL EDIT-301 SAFETY
AND
EFFICACY DATA FROM THE FIRST FOUR PATIENTS TREATED IN THE RUBY
TRIAL AND THE FIRST PATIENT TREATED IN THE EDITHAL TRIAL
    * EDITAS-EDIT-301 WAS WELL-TOLERATED,DEMONSTRATED SAFETY
WITH
MYELOABLATIVE CONDITIONING WITH BUSULFAN,AUTOLOGOUS
HEMATOPOIETIC STEM CELL TRANSPLANT

Source text for Eikon:  ID:nGNX6S1W33 
Further company coverage:  EDIT.O 

 ((Reuters.Briefs@thomsonreuters.com;))